Total income Q2: SEK 114.7 (180.8) million HY1: SEK 210.3 (304.9) million
EBITDA Q2: SEK 72.1 (102.7) million HY1: SEK 109.8 (132.4) million
Result before tax Q2: SEK 43.3 (36.5) million HY1: SEK 46.3 (6.0) million
Result per share after tax Q2: SEK 0.78 (0.75) HY1: SEK 0.84 (0.11)
Events in the second quarter
Sale and delivery of Stena Penguin.
Events after the end of the quarter
Sale of Stena Premium and Stena Progress.
Delivery to the buyers of Stena Premium.
Key figures Jan-Jun 2023
Total income, SEK million: 210.3 (304.9) of which result from ship sales 118.4 (39.0)
EBITDA, SEK million: 109.8 (132.4)
EBITDA, USD million: 10.5 (13.8)
Operating result, SEK million: 69.2 (46.5)
Result before tax, SEK million: 46.3 (6.0)
Result after tax, SEK million: 40.0 (5.2)
Equity ratio, %: 55 (20)
Return on equity, %: 39 (neg)
Available liquid funds, including unutilised credit facilities, SEK million: 189.7 (88.9)
Result per share after tax, SEK: 0.84 (0.11)
Equity per share, SEK: 9.78 (7.18)
Lost-time injuries: 0 (0)
This information is information that Concordia Maritime Aktiebolag (publ) is obliged to publish in accordance with the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was provided by the contact person above for publication on 24 August 2023 at 10.00 CEST.
CONTACT:
For more information, please contact: Erik Lewenhaupt CEO, Concordia Maritime AB Mob: +46 704 855 188 E-post: [email protected]
Martin Nerfeldt CFO, Concordia Maritime AB Tel: +45 88 938 661 Mob: +46 704 85 50 07 E-post: [email protected]
The two-year long slump in global private equity looks finally to be bottoming out, with the industry finding a footing from which to climb back, Bain & Company concludes...
Today, IXOPAY, announced the appointment of industry veteran Brady Harris as its new CEO. His appointment aligns with the recent merger of IXOPAY and TokenEx, highlighting a significant shift in the payments industry towards a multi-processor payment...
The9 Limited ("The9"), an established Internet company, today announced that it signed a definitive share purchase agreement (the "Agreement") with Wuhan Weixiang Science And Technology Co., Ltd. ("WeiXiang"), an AI-powered educational technology...
Keymed Biosciences Inc. (HKEX: 02162) today announced the long-term efficacy and safety data of a Phase III clinical trial of stapokibart injection in patients with moderate-to-severe atopic dermatitis (AD) has been released by way of oral...
NOTICE IS HEREBY GIVEN that the 25th annual general meeting of the shareholders of GigaMedia Limited (the "Company") will be held on June 27, 2024 at 11 a.m. local time at 8F, No.22, Lane 407, Sec.2, Tiding Blvd., Neihu District, Taipei, Taiwan,...
2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare solutions that address disparities in outcomes and health equity broadly, is pleased to announce the...